vs
Side-by-side financial comparison of AVALON HOLDINGS CORP (AWX) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
AVALON HOLDINGS CORP is the larger business by last-quarter revenue ($21.5M vs $20.4M, roughly 1.1× Sight Sciences, Inc.). AVALON HOLDINGS CORP runs the higher net margin — -1.7% vs -20.4%, a 18.8% gap on every dollar of revenue. On growth, AVALON HOLDINGS CORP posted the faster year-over-year revenue change (21.7% vs 6.9%). AVALON HOLDINGS CORP produced more free cash flow last quarter ($-166.0K vs $-2.0M). Over the past eight quarters, AVALON HOLDINGS CORP's revenue compounded faster (6.7% CAGR vs 2.9%).
Avalon Hill Games Inc. is a game company that publishes wargames and strategic board games. It has also published miniature wargaming rules, role-playing games and sports simulations. It is a subsidiary of Hasbro, and operates under the company's "Hasbro Gaming" division.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
AWX vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.5M | $20.4M |
| Net Profit | $-356.0K | $-4.2M |
| Gross Margin | 17.1% | 87.3% |
| Operating Margin | 0.4% | -18.0% |
| Net Margin | -1.7% | -20.4% |
| Revenue YoY | 21.7% | 6.9% |
| Net Profit YoY | 28.4% | 64.9% |
| EPS (diluted) | — | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.5M | $20.4M | ||
| Q3 25 | $25.7M | $19.9M | ||
| Q2 25 | $20.3M | $19.6M | ||
| Q1 25 | $16.1M | $17.5M | ||
| Q4 24 | $17.6M | $19.1M | ||
| Q3 24 | $24.2M | $20.2M | ||
| Q2 24 | $23.1M | $21.4M | ||
| Q1 24 | $18.9M | $19.3M |
| Q4 25 | $-356.0K | $-4.2M | ||
| Q3 25 | $1.9M | $-8.2M | ||
| Q2 25 | $274.0K | $-11.9M | ||
| Q1 25 | $-1.5M | $-14.2M | ||
| Q4 24 | $-497.0K | $-11.8M | ||
| Q3 24 | $1.8M | $-11.1M | ||
| Q2 24 | $954.0K | $-12.3M | ||
| Q1 24 | $-979.0K | $-16.3M |
| Q4 25 | 17.1% | 87.3% | ||
| Q3 25 | 23.7% | 86.4% | ||
| Q2 25 | 20.6% | 84.8% | ||
| Q1 25 | 14.8% | 86.2% | ||
| Q4 24 | 17.5% | 86.8% | ||
| Q3 24 | 24.6% | 83.9% | ||
| Q2 24 | 22.1% | 85.8% | ||
| Q1 24 | 16.2% | 85.5% |
| Q4 25 | 0.4% | -18.0% | ||
| Q3 25 | 9.1% | -39.7% | ||
| Q2 25 | 3.7% | -59.6% | ||
| Q1 25 | -7.2% | -79.2% | ||
| Q4 24 | -0.8% | -62.5% | ||
| Q3 24 | 9.4% | -55.7% | ||
| Q2 24 | 6.3% | -59.2% | ||
| Q1 24 | -2.7% | -76.4% |
| Q4 25 | -1.7% | -20.4% | ||
| Q3 25 | 7.4% | -41.0% | ||
| Q2 25 | 1.4% | -61.0% | ||
| Q1 25 | -9.3% | -80.8% | ||
| Q4 24 | -2.8% | -62.1% | ||
| Q3 24 | 7.6% | -54.9% | ||
| Q2 24 | 4.1% | -57.7% | ||
| Q1 24 | -5.2% | -84.4% |
| Q4 25 | — | $-0.07 | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | — | $-0.23 | ||
| Q1 25 | — | $-0.28 | ||
| Q4 24 | — | $-0.23 | ||
| Q3 24 | — | $-0.22 | ||
| Q2 24 | — | $-0.25 | ||
| Q1 24 | — | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.1M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $38.4M | $63.9M |
| Total Assets | $87.4M | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.1M | $92.0M | ||
| Q3 25 | $4.6M | $92.4M | ||
| Q2 25 | $3.7M | $101.5M | ||
| Q1 25 | $1.3M | $108.8M | ||
| Q4 24 | $2.8M | $120.4M | ||
| Q3 24 | $3.9M | $118.6M | ||
| Q2 24 | $3.8M | $118.2M | ||
| Q1 24 | $1.2M | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $38.4M | $63.9M | ||
| Q3 25 | $38.7M | $64.3M | ||
| Q2 25 | $36.8M | $70.0M | ||
| Q1 25 | $36.5M | $77.6M | ||
| Q4 24 | $38.0M | $87.5M | ||
| Q3 24 | $38.5M | $95.0M | ||
| Q2 24 | $36.7M | $101.6M | ||
| Q1 24 | $35.7M | $109.2M |
| Q4 25 | $87.4M | $115.3M | ||
| Q3 25 | $90.7M | $116.3M | ||
| Q2 25 | $88.1M | $122.0M | ||
| Q1 25 | $87.6M | $129.7M | ||
| Q4 24 | $86.2M | $142.8M | ||
| Q3 24 | $89.1M | $143.6M | ||
| Q2 24 | $91.7M | $149.7M | ||
| Q1 24 | $90.6M | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $278.0K | $-1.8M |
| Free Cash FlowOCF − Capex | $-166.0K | $-2.0M |
| FCF MarginFCF / Revenue | -0.8% | -9.7% |
| Capex IntensityCapex / Revenue | 2.1% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $278.0K | $-1.8M | ||
| Q3 25 | $1.5M | $-8.7M | ||
| Q2 25 | $3.0M | $-7.5M | ||
| Q1 25 | $-982.0K | $-11.6M | ||
| Q4 24 | $-579.0K | $-3.5M | ||
| Q3 24 | $342.0K | $362.0K | ||
| Q2 24 | $3.2M | $-9.5M | ||
| Q1 24 | $411.0K | $-9.8M |
| Q4 25 | $-166.0K | $-2.0M | ||
| Q3 25 | $852.0K | $-8.9M | ||
| Q2 25 | $2.7M | $-7.8M | ||
| Q1 25 | $-1.4M | — | ||
| Q4 24 | $-1.1M | $-3.6M | ||
| Q3 24 | $-660.0K | $311.0K | ||
| Q2 24 | $2.9M | $-9.5M | ||
| Q1 24 | $56.0K | $-9.9M |
| Q4 25 | -0.8% | -9.7% | ||
| Q3 25 | 3.3% | -44.7% | ||
| Q2 25 | 13.5% | -39.6% | ||
| Q1 25 | -8.5% | — | ||
| Q4 24 | -6.4% | -18.9% | ||
| Q3 24 | -2.7% | 1.5% | ||
| Q2 24 | 12.4% | -44.7% | ||
| Q1 24 | 0.3% | -51.4% |
| Q4 25 | 2.1% | 0.8% | ||
| Q3 25 | 2.3% | 0.9% | ||
| Q2 25 | 1.4% | 1.1% | ||
| Q1 25 | 2.4% | 0.0% | ||
| Q4 24 | 3.1% | 0.7% | ||
| Q3 24 | 4.1% | 0.3% | ||
| Q2 24 | 1.5% | 0.4% | ||
| Q1 24 | 1.9% | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | 0.76× | — | ||
| Q2 25 | 11.07× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.19× | — | ||
| Q2 24 | 3.35× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AWX
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
